A Study of MK-5684 in China Participants With Metastatic Castration-Resistant Prostate Cancer (mCRPC) (MK-5684-001)
Conditions: Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer Interventions: Drug: MK-5684; Drug: Dexamethasone; Drug: Fludrocortisone; Drug: Hydrocortisone Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 17, 2023 Category: Research Source Type: clinical trials
MK-2870 in Post Platinum and Post Immunotherapy Endometrial Cancer (MK-2870-005)
Conditions: Endometrial Cancer Interventions: Biological: MK-2870; Drug: Doxorubicin; Drug: Paclitaxel Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 15, 2023 Category: Research Source Type: clinical trials
A Study of Pembrolizumab With Trastuzumab and Chemotherapy in People With Esophagogastric Cancer
Conditions: Esophageal Cancer; Gastric Adenocarcinoma; HER2 Gene Mutation Interventions: Drug: Pembrolizumab; Drug: Trastuzumab Sponsors: Memorial Sloan Kettering Cancer Center; Genentech, Inc.; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 8, 2023 Category: Research Source Type: clinical trials
A Study to Evaluate the Safety and the Activity of S095029 as Part of Combination Therapy in Advanced Gastroesophageal Junction/Gastric Cancers.
Conditions: MSI-H/dMMR Gastroesophageal-junction Cancer; MSI-H/dMMR Gastric Cancer Interventions: Drug: S095029; Drug: Pembrolizumab 200 mg Sponsors: Servier Bio-Innovation LLC; Merck Sharp& Dohme LLC; Institut de Recherches Internationales Servier Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
Study Evaluating Pembrolizumab +/- Olaparib in TLS Positive Selected Resectable STS Followed by Adjuvant Pembrolizumab
Conditions: Cancer Interventions: Drug: Pembrolizumab; Drug: Pembrolizumab and Olaparib; Drug: Pembrolizumab adjuvant Sponsors: Gustave Roussy, Cancer Campus, Grand Paris; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 3, 2023 Category: Research Source Type: clinical trials
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
Conditions: Non-segmental Vitiligo Interventions: Biological: MK-6194; Drug: Placebo Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 2, 2023 Category: Research Source Type: clinical trials
Neuromuscular Blockade Comparison for GI-2 Recovery After Bowel Resection
Conditions: Intestinal Disease Interventions: Drug: Neostigmine Injectable Solution; Drug: Sugammadex injection Sponsors: University of California, Irvine; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study of Lenvatinib, Pembrolizumab, and Fulvestrant in People With Breast Cancer
Conditions: Metastatic Breast Cancer Interventions: Drug: Lenvatinib; Drug: Pembrolizuma; Drug: Fulvestrant Sponsors: Memorial Sloan Kettering Cancer Center; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - November 1, 2023 Category: Research Source Type: clinical trials
A Study of MK-5684 in Japanese Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-5684-005)
Conditions: Prostatic Neoplasms; Metastatic Castration-Resistant Prostate Cancer Interventions: Drug: MK-5684; Drug: Dexamethasone; Drug: Fludrocortisone acetate; Drug: Hydrocortisone Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 27, 2023 Category: Research Source Type: clinical trials
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)
Conditions: Non-Small Cell Lung Cancer; Renal Cell Carcinoma; Melanoma Interventions: Biological: Pembrolizumab co-formulated with hyaluronidase; Biological: Pembrolizumab Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
Immunology of Ebola Vaccine
Conditions: Ebola Virus Disease Interventions: Biological: Recombinant Vesicular Stomatitis Vaccine for Ebola (rVSV ∆G-ZEBOV-GP) Sponsors: Emory University; Washington University School of Medicine; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 25, 2023 Category: Research Source Type: clinical trials
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)
Conditions: Triple Negative Breast Cancer Interventions: Drug: Sacituzumab govitecan; Drug: Pembrolizumab Sponsors: West German Study Group; Gilead Sciences; Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 13, 2023 Category: Research Source Type: clinical trials
A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006)
Conditions: Essential Thrombocythemia Interventions: Drug: Bomedemstat; Drug: Anagrelide; Drug: Busulfan; Drug: Interferon alfa/pegylated interferon alfa; Drug: Ruxolitinib Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 12, 2023 Category: Research Source Type: clinical trials
A Study of V940 Plus Pembrolizumab (MK-3475) Versus Placebo Plus Pembrolizumab in Participants With Non-small Cell Lung Cancer (V940-002)
Conditions: Non-small Cell Lung Cancer Interventions: Biological: V940; Biological: Pembrolizumab; Other: Placebo Sponsors: Merck Sharp& Dohme LLC; ModernaTX, Inc. Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 11, 2023 Category: Research Source Type: clinical trials
MK-2870 Versus Chemotherapy in Previously Treated Advanced or Metastatic Nonsquamous Non-small Cell Lung Cancer (NSCLC) With EGFR Mutations or Other Genomic Alterations (MK-2870-004)
Conditions: Non-small Cell Lung Cancer (NSCLC) Interventions: Biological: MK-2870; Drug: Docetaxel; Drug: Pemetrexed Sponsors: Merck Sharp& Dohme LLC Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - October 10, 2023 Category: Research Source Type: clinical trials
